'On consolidated basis
Quarter ended March 2025 compared with Quarter ended March 2024.
Net sales (including other operating income) of Sanofi India has increased 4.91% to Rs 535.9 crore. Operating profit margin has jumped from 26.84% to 32.08%, leading to 25.38% rise in operating profit to Rs 171.90 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 20.74% to 16.63%. Purchase of finished goods cost rose from 8.50% to 18.48%. Employee cost decreased from 18.74% to 11.82%. Other expenses rose from 15.05% to 15.31%.
Other income fell 5.71% to Rs 3.3 crore. PBIDT rose 24.61% to Rs 175.2 crore.
PBDT rose 24.66% to Rs 174.9 crore. Provision for depreciation rose 5.49% to Rs 9.6 crore.
Profit before tax grew 25.99% to Rs 165.30 crore. Share of profit/loss were nil in both the periods....
Pleaselogin & subscribe to view the full report.
More Reports
|
|